Skip to content

Released Jun 1, 2020, before the open

10-Q filed Jun 1, 2020, 62 days after period end · 0001104659-20-067982

Q1 2020 · 10-Q
Revenue$21.65M+107.4% vs Q1 2019+21.9% vs Q4 2019
Net Income$1.67MN/M vs Q1 2019+472.9% vs Q4 2019
EPS Diluted$0.10N/M vs Q1 2019+400.0% vs Q4 2019
Operating Income$4,693,000N/M
Operating Cash Flow-$7,117,000N/M
Free Cash Flowderived-$7,183,000N/M
Margins · derived
Operating margin21.7%+74.7 pt vs Q1 2019
Net margin7.7%+77.3 pt vs Q1 2019

What the release said

The release

Same quarter

MetricQ1 2020Q1 2019Q1 2018Q1 2017
Revenue$21.65M$10.44M$4.55M$2.89M
Net Income$1.67M-$7.26M-$7.24M-$59.15M
EPS Diluted$0.10-$0.50-$0.50-$0.48

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR